• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一目了然的 COVID-19:变种、药物设计和疗法的最新概述。

COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.

机构信息

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.

Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70126 Bari, Italy.

出版信息

Viruses. 2022 Mar 10;14(3):573. doi: 10.3390/v14030573.

DOI:10.3390/v14030573
PMID:35336980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8950852/
Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a member of the Coronavirus family which caused the worldwide pandemic of human respiratory illness coronavirus disease 2019 (COVID-19). Presumably emerging at the end of 2019, it poses a severe threat to public health and safety, with a high incidence of transmission, predominately through aerosols and/or direct contact with infected surfaces. In 2020, the search for vaccines began, leading to the obtaining of, to date, about twenty COVID-19 vaccines approved for use in at least one country. However, COVID-19 continues to spread and new genetic mutations and variants have been discovered, requiring pharmacological treatments. The most common therapies for COVID-19 are represented by antiviral and antimalarial agents, antibiotics, immunomodulators, angiotensin II receptor blockers, bradykinin B2 receptor antagonists and corticosteroids. In addition, nutraceuticals, vitamins D and C, omega-3 fatty acids and probiotics are under study. Finally, drug repositioning, which concerns the investigation of existing drugs for new therapeutic target indications, has been widely proposed in the literature for COVID-19 therapies. Considering the importance of this ongoing global public health emergency, this review aims to offer a synthetic up-to-date overview regarding diagnoses, variants and vaccines for COVID-19, with particular attention paid to the adopted treatments.

摘要

严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)是冠状病毒科的一个成员,导致了 2019 年全球人类呼吸道疾病冠状病毒病 2019(COVID-19)大流行。据推测,它在 2019 年底出现,对公众健康和安全构成严重威胁,具有很高的传播发病率,主要通过气溶胶和/或直接接触受感染的表面传播。2020 年,开始寻找疫苗,导致迄今为止获得了约二十种 COVID-19 疫苗,至少在一个国家获得批准使用。然而,COVID-19 仍在继续传播,新的遗传突变和变体已经被发现,需要药物治疗。COVID-19 的最常见治疗方法包括抗病毒和抗疟药物、抗生素、免疫调节剂、血管紧张素 II 受体阻滞剂、缓激肽 B2 受体拮抗剂和皮质类固醇。此外,正在研究营养保健品、维生素 D 和 C、ω-3 脂肪酸和益生菌。最后,药物再定位,即研究现有药物用于新的治疗靶点适应症,在 COVID-19 治疗方面已在文献中广泛提出。鉴于这一持续的全球公共卫生紧急情况的重要性,本综述旨在提供有关 COVID-19 的诊断、变体和疫苗的综合最新概述,特别关注所采用的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/8950852/07f6b81cdd28/viruses-14-00573-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/8950852/3041322acdf5/viruses-14-00573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/8950852/07f6b81cdd28/viruses-14-00573-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/8950852/3041322acdf5/viruses-14-00573-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/8950852/07f6b81cdd28/viruses-14-00573-g002.jpg

相似文献

1
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies.一目了然的 COVID-19:变种、药物设计和疗法的最新概述。
Viruses. 2022 Mar 10;14(3):573. doi: 10.3390/v14030573.
2
COVID-19: Potential Repurposing Drugs.COVID-19:潜在的再利用药物。
Infect Disord Drug Targets. 2022;22(1):e110122191924. doi: 10.2174/1871526521666210301143441.
3
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.SARS-CoV-2 感染的分子机制与分子治疗。
Curr Mol Med. 2022;22(7):621-639. doi: 10.2174/1566524021666211013121831.
4
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].[氯丙嗪在新冠病毒肺炎治疗中的重新应用:恢复研究]
Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29.
5
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.SARS-CoV-2:感染引起的免疫反应和疫苗及治疗的发展。
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
6
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.药物重定位方法对抗冠状病毒:潜在药物和药物靶点。
Med Res Rev. 2021 May;41(3):1375-1426. doi: 10.1002/med.21763. Epub 2020 Dec 5.
7
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.对 COVID-19 目前进展的批判性综述:疫苗、抗病毒药物和治疗性抗体的开发。
J Biomed Sci. 2022 Sep 12;29(1):68. doi: 10.1186/s12929-022-00852-9.
8
Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations (Archived)针对轻度至中度症状的高危冠状病毒(COVID-19)患者的单克隆抗体疗法(存档)
9
COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics.2019冠状病毒病大流行:流行病学、发病机制、诊断以及潜在疫苗和治疗方法概述
Ther Deliv. 2020 Apr;11(4):245-268. doi: 10.4155/tde-2020-0035. Epub 2020 May 12.
10
Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.SARS-CoV-2 及其新兴变异株的进入抑制剂的发现和评估。
J Virol. 2021 Nov 23;95(24):e0143721. doi: 10.1128/JVI.01437-21. Epub 2021 Sep 22.

引用本文的文献

1
Vitamin D status in children with COVID-19: does it affect the development of long COVID and its symptoms?新冠病毒感染儿童的维生素D状况:它是否会影响新冠后长期症状的发生及其症状?
Front Pediatr. 2025 Feb 14;13:1507169. doi: 10.3389/fped.2025.1507169. eCollection 2025.
2
Predicting the Anti-SARS-CoV-2 Potential of Isoquinoline Alkaloids from Brazilian Siparunaceae Species Using Chemometric Tools.运用化学计量学工具预测巴西锡叶藤科植物中异喹啉生物碱的抗SARS-CoV-2潜力
Int J Mol Sci. 2025 Jan 13;26(2):633. doi: 10.3390/ijms26020633.
3
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.

本文引用的文献

1
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.鸡蛋来源的抗 SARS-CoV-2 免疫球蛋白 Y(IgY)具有广泛的变体活性,可作为 COVID-19 的鼻腔预防用药。
Front Immunol. 2022 Jun 1;13:899617. doi: 10.3389/fimmu.2022.899617. eCollection 2022.
2
Quinazoline-Schiff base conjugates: study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins.喹唑啉-席夫碱共轭物:作为冠状病毒(SARS-CoV-2)蛋白多靶点抑制剂的研究及ADMET预测
RSC Adv. 2020 Sep 15;10(56):34033-34045. doi: 10.1039/d0ra06424f. eCollection 2020 Sep 10.
3
靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)关键蛋白的共价抑制剂的结构基础研究进展
Curr Med Chem. 2025;32(19):3790-3824. doi: 10.2174/0109298673323348241208080419.
4
Arterial floating mural thrombi are a characteristic imaging pattern in SARS-CoV-2-related ischemic stroke.动脉漂浮性壁栓是 SARS-CoV-2 相关缺血性卒中的一种特征性影像学表现。
PLoS One. 2024 Oct 25;19(10):e0311622. doi: 10.1371/journal.pone.0311622. eCollection 2024.
5
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.新型疗法和策略以遏制 HIV 感染,重点关注巨噬细胞和病毒储存库。
Viruses. 2024 Sep 18;16(9):1484. doi: 10.3390/v16091484.
6
-An Extensive Review Focused on Recent Studies.- 一项聚焦近期研究的全面综述。
Foods. 2024 Jul 8;13(13):2155. doi: 10.3390/foods13132155.
7
The Ongoing Impact of COVID-19 on Pediatric Obesity.新冠病毒病对儿童肥胖的持续影响
Pediatr Rep. 2024 Feb 2;16(1):135-150. doi: 10.3390/pediatric16010013.
8
CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.降钙素基因相关肽(CGRP)拮抗剂与生酮饮食治疗偏头痛。
Medicina (Kaunas). 2024 Jan 15;60(1):163. doi: 10.3390/medicina60010163.
9
A Comprehensive Review on the State of the Art of Breast Cancers in Italy.意大利乳腺癌现状的全面综述。
Curr Med Chem. 2024;31(18):2486-2506. doi: 10.2174/0109298673283289231214095230.
10
Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections.钌(II)配合物作为对抗癌症和病毒感染的有前景的双活性药物。
Pharmaceuticals (Basel). 2023 Dec 15;16(12):1729. doi: 10.3390/ph16121729.
Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens.
从人类临床标本中分离出的 SARS-CoV-2 奥密克戎变异株的分离与基因组特征。
Viruses. 2022 Feb 24;14(3):461. doi: 10.3390/v14030461.
4
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.针对 SARS-CoV-2 奥密克戎 B.1.1.529 分离株的治疗性抗体的体外评估。
Sci Rep. 2022 Mar 18;12(1):4683. doi: 10.1038/s41598-022-08559-5.
5
Evaluating the Evidence in Clinical Studies of Vitamin D in COVID-19.评估维生素 D 治疗 COVID-19 的临床研究证据。
Nutrients. 2022 Jan 21;14(3):464. doi: 10.3390/nu14030464.
6
A Review on the Antimicrobial Activity of Schiff Bases: Data Collection and Recent Studies.席夫碱抗菌活性综述:数据收集与近期研究
Antibiotics (Basel). 2022 Feb 1;11(2):191. doi: 10.3390/antibiotics11020191.
7
Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies.多药耐药性(MDR):药理学治疗中的普遍现象。
Molecules. 2022 Jan 18;27(3):616. doi: 10.3390/molecules27030616.
8
Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.药用植物在抑制新型冠状病毒以及新冠后并发症管理中的作用。
Phytomedicine. 2022 Apr;98:153930. doi: 10.1016/j.phymed.2022.153930. Epub 2022 Jan 5.
9
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.瑞德西韦、莫努匹韦和奈玛特韦仍对 SARS-CoV-2 奥密克戎和其他关注变体保持活性。
Antiviral Res. 2022 Feb;198:105252. doi: 10.1016/j.antiviral.2022.105252. Epub 2022 Jan 24.
10
Will the COVID-19 pandemic end with the Delta and Omicron variants?新冠疫情会随着德尔塔和奥密克戎变种而结束吗?
Environ Chem Lett. 2022;20(4):2215-2225. doi: 10.1007/s10311-021-01369-7. Epub 2022 Jan 15.